Diagnostics
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA’s signal to start shipping the vaccines.
C2i Genomics plans to make sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the world, regardless of where patients or clinical trials are located.
Depression is the first indication, but other neurological conditions are being planned.
Cue Health went public on September 24 on the Nasdaq securities exchange under the ticker symbol HLTH.
Eriksson said that HMNC Brain Health is a pioneer in developing precision medicine for the psychiatric space.
Several life sciences companies were sprinkled throughout this year’s list. Here’s a look at a few of the honorees.
The duo’s mission is to identify more patients who could benefit from precision medicines by deploying more CDx tests to healthcare providers.
This is an effort to eliminate severe adverse reactions by matching the birth control to the genetics and hormones of the individual.
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
PRESS RELEASES
